These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 15134556)
41. Glycoprotein IIb/IIIa blockers in non-ST elevation acute coronary syndromes: only for well defined subgroups or a therapeutic option for all patients? Verheugt FW J Thromb Thrombolysis; 2003 Apr; 15(2):81-4. PubMed ID: 14618073 [TBL] [Abstract][Full Text] [Related]
43. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. Chew DP; Moliterno DJ J Am Coll Cardiol; 2000 Dec; 36(7):2028-35. PubMed ID: 11127436 [TBL] [Abstract][Full Text] [Related]
44. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Mak KH; Effron MB; Moliterno DJ Drugs Aging; 2000 Mar; 16(3):179-87. PubMed ID: 10803858 [TBL] [Abstract][Full Text] [Related]
45. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. Chong PH Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033 [TBL] [Abstract][Full Text] [Related]
46. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188 [TBL] [Abstract][Full Text] [Related]
47. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G; Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353 [TBL] [Abstract][Full Text] [Related]
48. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist. Quinn MJ; Cox D; Foley JB; Fitzgerald DJ J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104 [TBL] [Abstract][Full Text] [Related]
49. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
50. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Casterella PJ; Revenaugh JR; Burke JL; Pearson RR; Bair TL; May HT; Horne B; Anderson JL; Muhlestein JB J Invasive Cardiol; 2008 Mar; 20(3):94-8. PubMed ID: 18316822 [TBL] [Abstract][Full Text] [Related]
55. Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports. Kong DF; Califf RM Drugs; 1999 Oct; 58(4):609-20. PubMed ID: 10551433 [TBL] [Abstract][Full Text] [Related]
56. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601 [TBL] [Abstract][Full Text] [Related]
57. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. Campbell KR; Ohman EM; Cantor W; Lincoff AM Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178 [TBL] [Abstract][Full Text] [Related]